# A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

> **NCT05203510** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **United Therapeutics** · enrollment: 52 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Parenteral Treprostinil
- **DRUG:** Oral Treprostinil

## Key facts

- **NCT ID:** NCT05203510
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-20
- **Primary completion:** 2026-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203510, "A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05203510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*